CJC-1295 With DAC vs Without DAC: Half-Life and Research Design

Background

Native GHRH has a circulating half-life of ~7 minutes, dominated by DPP-4-mediated cleavage at the N-terminus. CJC-1295 (no DAC), with four amino-acid substitutions, extends this to ~30 minutes. The DAC (Drug Affinity Complex) modification takes that further — to 6–8 days — fundamentally changing the pharmacodynamics and what the molecule is useful for in research.

What DAC is, chemically

DAC is a maleimidopropionic acid (MPA) linker conjugated to the C-terminus of modified GRF(1-29). The maleimide group forms a covalent thioether bond with a reactive cysteine residue on serum albumin (Cys-34 on human albumin). Key consequences:

• CJC-1295 becomes covalently tethered to albumin shortly after administration
• Albumin's half-life (~19 days in humans) becomes the rate-limiting factor for CJC-1295 clearance
• Circulating CJC-1295-DAC concentration remains relatively stable over days rather than oscillating with each injection

Pharmacodynamic consequence

The biological difference is not just longer — it's qualitatively different:

CJC-1295 no-DAC produces a pulsatile GH response similar to endogenous GHRH:

• Sharp GH peak within minutes of administration
• Return to baseline within 1–2 hours
• Preserves normal pulsatile rhythm that is thought to underpin physiological IGF-1 generation

CJC-1295 with DAC produces a sustained GH/IGF-1 elevation:

• GH pulse amplitude preserved but baseline GH elevated
• IGF-1 remains elevated continuously for days
• Loss of pulsatility — receptor desensitization dynamics differ from physiological state

Pulsatility matters. Some research suggests continuous GH exposure drives different hepatic gene expression patterns than pulsatile exposure (e.g., sex-specific cytochrome P450 induction in rodents). Study design should consider whether sustained or pulsatile stimulation better matches the endpoint.

Research design implications

Use no-DAC when:

• You need physiological pulse dynamics
• Acute receptor engagement is the endpoint
• You're pairing with GHRPs in combination studies (pulsatility matters for synergy)
• You need frequent dosing control over concentration-time profile

Use DAC when:

• You want to test sustained IGF-1 elevation as the independent variable
• The study is long-duration (weeks) and frequent injections would confound results
• You're investigating chronic GH/IGF-1 exposure phenotypes
• You need stable plasma concentration without frequent intervention

What the literature shows

• PK studies in rats demonstrate ~8-day effective GH stimulation after a single DAC-CJC administration
• IGF-1 elevation is dose-dependent but plateaus at a dose-dependent ceiling
• Tachyphylaxis (reduced GH response) emerges faster with DAC than no-DAC in chronic administration models
• Receptor downregulation kinetics differ substantially between the two

Handling notes — no differences

From a handling standpoint, both variants are treated identically:

• Lyophilized powder; store at -20°C light-protected
• Reconstitute with sterile/bacteriostatic water
• Stability ~4 weeks at 2–8°C reconstituted
• HPLC purity ≥99.0%; MS identity; batch-specific COA

The DAC linker is stable under these conditions.

Related reading

• /research/cjc-1295-no-dac — no-DAC compound profile
• /compare/cjc-1295-dac-vs-no-dac — direct comparison
• /blog/sermorelin-vs-cjc-1295-ghrh-analog-research — GHRH-class comparison
• /blog/cjc-1295-ipamorelin-mechanism — combination pharmacology
• /category/muscle-growth-research — broader category

RUO disclaimer

For laboratory research use only. Not for human consumption. We do not provide dosing schedules — consult published literature and institutional oversight for study design.